

BioLargo, Inc.

1 ? . Ž ((f \$ L & \$ + - , - , \$, %
 B 5 . Ž % * (* , - * ' \$ *)
 5 1 Ž * % & ' - & , \$ \$ + \$ \$ \$
 U W j c b 4 d f c U W j Y j b j Y g h c f g " V e a

14:55 23 Sep 2019

BioLargo subsidiary receives FDA clearance to market Clyra Wound Irrigation Solution

BioLargo Inc (OTCMKTS:BLGO) subsidiary Clyra Medical Technologies has received 510(k) clearance from the US Food and Drug Administration to market its Clyra Wound Irrigation Solution, the environmental engineering company said Monday.

The product is designed for cleansing, irrigating, and debriding dermal wounds and burns, in addition to moistening and lubricating absorbent wound dressings.

BioLargo said the wound solution is the first of several products that will feature the company's platform antimicrobial technology, which provides sustained antimicrobial efficacy (including biofilm) without causing harm to the tissue.

READ: BioLargo boosts revenue, cuts loss in 2Q

"This is a pivotal milestone in our mission to build a world-class portfolio of unique products and solutions to help heal patients," said Clyra President Steve Harrison in a statement.

"This FDA clearance is a critical step in the development of our product portfolio and the execution of our commercial strategy. Next up are clinical trials for high-value applications for this platform product."

BioLargo CEO Dennis Calvert added that the FDA decision "illustrates our dedication to carry high-impact technology solutions from concept to completion as we strive to solve pressing issues affecting countless people across the planet."

The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care.

BioLargo's stock recently traded 2.5% higher to \$0.23 a share on the OTC Market.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 0.17

Market Cap: \$27.87 m

1 Year Share Price Graph



Share Information

Code: BLGO

Listing: OTCMKTS

52 week	High	Low
	0.395	0.1012

Sector: Manufacturing & engineering

Website: biolargo.com

Company Synopsis:

BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care.

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BioLargo, Inc. named herein, including the promotion by the Company of BioLargo, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).